sponsored content
March 5, 2026
In this podcast, we discuss the first U.S. FDA‑market authorized spectacle lens for correcting myopia and slowing its progression in children aged 6–12 at the initiation of treatment — the Essilor® Stellest® spectacle lens*. EssilorLuxottica experts Dr. Jason Shen, Director of Vision Science Research, North America, and Dr. Monica Jong, Head of Medical Affairs, North America, explain what this authorization means, the clinical evidence behind the lenses, and how this development may support evidence-based myopia management in clinical practice in the U.S.
Listen to the full discussion here:
*Essilor Stellest lens regulatory status and product availability may vary by country. U.S. FDA authorization and indications for use are based solely on clinical trial data from the U.S.
